#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Disrupted	_
1-2	10-17	Network	_
1-3	18-23	Cross	_
1-4	24-28	Talk	_
1-5	29-30	,	_
1-6	31-42	Hippocampal	_
1-7	43-54	Dysfunction	_
1-8	55-58	and	_
1-9	59-73	Hallucinations	_
1-10	74-76	in	_
1-11	77-90	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	91-105	Hallucinations	_
1-13	106-118	characterize	_
1-14	119-132	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	133-134	,	_
1-16	135-139	with	_
1-17	140-153	approximately	_
1-18	154-156	59	_
1-19	157-158	%	_
1-20	159-161	of	_
1-21	162-170	patients	_
1-22	171-180	reporting	_
1-23	181-189	auditory	_
1-24	190-204	hallucinations	_
1-25	205-208	and	_
1-26	209-211	27	_
1-27	212-213	%	_
1-28	214-223	reporting	_
1-29	224-230	visual	_
1-30	231-245	hallucinations	_
1-31	246-247	.	_

2-1	248-253	Prior	_
2-2	254-266	neuroimaging	_
2-3	267-274	studies	_
2-4	275-282	suggest	_
2-5	283-287	that	_
2-6	288-302	hallucinations	_
2-7	303-306	are	_
2-8	307-313	linked	_
2-9	314-316	to	_
2-10	317-326	disrupted	_
2-11	327-340	communication	_
2-12	341-347	across	_
2-13	348-359	distributed	_
2-14	360-361	(	_
2-15	362-369	sensory	_
2-16	370-371	,	_
2-17	372-391	salience-monitoring	_
2-18	392-395	and	_
2-19	396-407	subcortical	_
2-20	408-409	)	_
2-21	410-418	networks	_
2-22	419-420	.	_

3-1	421-424	Yet	_
3-2	425-426	,	_
3-3	427-430	our	_
3-4	431-444	understanding	_
3-5	445-447	of	_
3-6	448-451	the	_
3-7	452-470	neurophysiological	_
3-8	471-481	mechanisms	_
3-9	482-486	that	_
3-10	487-495	underlie	_
3-11	496-504	auditory	_
3-12	505-508	and	_
3-13	509-515	visual	_
3-14	516-530	hallucinations	_
3-15	531-533	in	_
3-16	534-547	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	548-555	remains	_
3-18	556-563	limited	_
3-19	564-565	.	_

4-1	566-570	This	_
4-2	571-576	study	_
4-3	577-587	integrates	_
4-4	588-591	two	_
4-5	592-605	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-6	606-616	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-7	617-625	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-8	626-635	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-9	636-643	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-10	644-645	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-11	646-650	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-12	651-652	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-13	653-661	analysis	_
4-14	662-669	methods	_
4-15	670-671	–	_
4-16	672-682	amplitudes	_
4-17	683-685	of	_
4-18	686-699	low-frequency	_
4-19	700-712	fluctuations	_
4-20	713-714	(	_
4-21	715-719	ALFF	_
4-22	720-721	)	_
4-23	722-725	and	_
4-24	726-736	functional	_
4-25	737-744	network	_
4-26	745-757	connectivity	_
4-27	758-759	(	_
4-28	760-763	FNC	_
4-29	764-765	)	_
4-30	766-767	–	_
4-31	768-770	to	_
4-32	771-778	explore	_
4-33	779-782	the	_
4-34	783-793	hypotheses	_
4-35	794-798	that	_
4-36	799-800	(	_
4-37	801-802	1	_
4-38	803-804	)	_
4-39	805-813	abnormal	_
4-40	814-817	FNC	_
4-41	818-825	between	_
4-42	826-834	salience	_
4-43	835-838	and	_
4-44	839-846	sensory	_
4-45	847-848	(	_
4-46	849-864	visual/auditory	_
4-47	865-866	)	_
4-48	867-875	networks	_
4-49	876-885	underlies	_
4-50	886-900	hallucinations	_
4-51	901-903	in	_
4-52	904-917	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-53	918-919	,	_
4-54	920-923	and	_
4-55	924-925	(	_
4-56	926-927	2	_
4-57	928-929	)	_
4-58	930-939	disrupted	_
4-59	940-951	hippocampal	_
4-60	952-964	oscillations	_
4-61	965-966	(	_
4-62	967-969	as	_
4-63	970-978	measured	_
4-64	979-981	by	_
4-65	982-993	hippocampal	_
4-66	994-998	ALFF	_
4-67	999-1000	)	_
4-68	1001-1006	beget	_
4-69	1007-1014	changes	_
4-70	1015-1017	in	_
4-71	1018-1021	FNC	_
4-72	1022-1028	linked	_
4-73	1029-1031	to	_
4-74	1032-1046	hallucinations	_
4-75	1047-1048	.	_

5-1	1049-1052	Our	_
5-2	1053-1058	first	_
5-3	1059-1069	hypothesis	_
5-4	1070-1073	was	_
5-5	1074-1083	supported	_
5-6	1084-1086	by	_
5-7	1087-1090	the	_
5-8	1091-1098	finding	_
5-9	1099-1103	that	_
5-10	1104-1117	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-11	1118-1126	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-12	1127-1136	reporting	_
5-13	1137-1151	hallucinations	_
5-14	1152-1156	have	_
5-15	1157-1163	higher	_
5-16	1164-1167	FNC	_
5-17	1168-1175	between	_
5-18	1176-1179	the	_
5-19	1180-1188	salience	_
5-20	1189-1196	network	_
5-21	1197-1200	and	_
5-22	1201-1203	an	_
5-23	1204-1215	associative	_
5-24	1216-1224	auditory	_
5-25	1225-1232	network	_
5-26	1233-1241	relative	_
5-27	1242-1244	to	_
5-28	1245-1252	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-29	1253-1261	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-30	1262-1263	.	_

6-1	1264-1275	Hippocampal	_
6-2	1276-1280	ALFF	_
6-3	1281-1284	was	_
6-4	1285-1295	negatively	_
6-5	1296-1306	associated	_
6-6	1307-1311	with	_
6-7	1312-1315	FNC	_
6-8	1316-1323	between	_
6-9	1324-1331	primary	_
6-10	1332-1340	auditory	_
6-11	1341-1347	cortex	_
6-12	1348-1351	and	_
6-13	1352-1355	the	_
6-14	1356-1364	salience	_
6-15	1365-1372	network	_
6-16	1373-1375	in	_
6-17	1376-1383	healthy	_
6-18	1384-1392	subjects	_
6-19	1393-1394	,	_
6-20	1395-1398	but	_
6-21	1399-1402	was	_
6-22	1403-1413	positively	_
6-23	1414-1424	associated	_
6-24	1425-1429	with	_
6-25	1430-1433	FNC	_
6-26	1434-1441	between	_
6-27	1442-1447	these	_
6-28	1448-1456	networks	_
6-29	1457-1459	in	_
6-30	1460-1468	patients	_
6-31	1469-1478	reporting	_
6-32	1479-1493	hallucinations	_
6-33	1494-1495	.	_

7-1	1496-1501	These	_
7-2	1502-1510	findings	_
7-3	1511-1518	provide	_
7-4	1519-1527	indirect	_
7-5	1528-1535	support	_
7-6	1536-1544	favoring	_
7-7	1545-1548	our	_
7-8	1549-1555	second	_
7-9	1556-1566	hypothesis	_
7-10	1567-1568	.	_

8-1	1569-1571	We	_
8-2	1572-1579	suggest	_
8-3	1580-1586	future	_
8-4	1587-1594	studies	_
8-5	1595-1604	integrate	_
8-6	1605-1609	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-7	1610-1614	with	_
8-8	1615-1635	electroencephalogram	_
8-9	1636-1637	(	_
8-10	1638-1641	EEG	_
8-11	1642-1643	)	_
8-12	1644-1650	and/or	_
8-13	1651-1671	magnetoencephalogram	_
8-14	1672-1673	(	_
8-15	1674-1677	MEG	_
8-16	1678-1679	)	_
8-17	1680-1687	methods	_
8-18	1688-1690	to	_
8-19	1691-1699	directly	_
8-20	1700-1705	probe	_
8-21	1706-1709	the	_
8-22	1710-1718	temporal	_
8-23	1719-1727	relation	_
8-24	1728-1735	between	_
8-25	1736-1743	altered	_
8-26	1744-1755	hippocampal	_
8-27	1756-1768	oscillations	_
8-28	1769-1772	and	_
8-29	1773-1780	changes	_
8-30	1781-1783	in	_
8-31	1784-1797	cross-network	_
8-32	1798-1808	functional	_
8-33	1809-1822	communication	_
8-34	1823-1824	.	_

9-1	1825-1826	2	_
9-2	1827-1828	.	_

10-1	1829-1841	Experimental	_
10-2	1842-1851	materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1852-1855	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1856-1863	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-5	1864-1867	2.1	_
10-6	1868-1869	.	_

11-1	1870-1878	Subjects	_
11-2	1879-1881	We	_
11-3	1882-1890	analyzed	_
11-4	1891-1894	294	_
11-5	1895-1908	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
11-6	1909-1913	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
11-7	1914-1919	scans	_
11-8	1920-1924	from	_
11-9	1925-1928	the	_
11-10	1929-1939	Functional	_
11-11	1940-1950	Biomedical	_
11-12	1951-1962	Informatics	_
11-13	1963-1971	Research	_
11-14	1972-1979	Network	_
11-15	1980-1981	(	_
11-16	1982-1987	FBIRN	_
11-17	1988-1989	)	_
11-18	1990-1997	dataset	_
11-19	1998-1999	.	_

12-1	2000-2013	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-2	2014-2022	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-3	2023-2024	(	_
12-4	2025-2030	n=141	_
12-5	2031-2032	)	_
12-6	2033-2036	and	_
12-7	2037-2039	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-8	2040-2041	(	_
12-9	2042-2047	n=153	_
12-10	2048-2049	)	_
12-11	2050-2054	were	_
12-12	2055-2062	matched	_
12-13	2063-2066	for	_
12-14	2067-2070	age	_
12-15	2071-2072	,	_
12-16	2073-2081	reported	_
12-17	2082-2088	gender	_
12-18	2089-2090	,	_
12-19	2091-2094	and	_
12-20	2095-2105	handedness	_
12-21	2106-2107	(	_
12-22	2108-2113	Table	_
12-23	2114-2115	1	_
12-24	2116-2117	)	_
12-25	2118-2119	.	_

13-1	2120-2123	Raw	_
13-2	2124-2131	imaging	_
13-3	2132-2136	data	_
13-4	2137-2141	were	_
13-5	2142-2151	collected	_
13-6	2152-2156	from	_
13-7	2157-2160	six	_
13-8	2161-2166	sites	_
13-9	2167-2168	;	_
13-10	2169-2176	written	_
13-11	2177-2185	informed	_
13-12	2186-2193	consent	_
13-13	2194-2197	was	_
13-14	2198-2206	obtained	_
13-15	2207-2211	from	_
13-16	2212-2215	all	_
13-17	2216-2228	participants	_
13-18	2229-2230	.	_

14-1	2231-2234	The	_
14-2	2235-2242	consent	_
14-3	2243-2250	process	_
14-4	2251-2254	was	_
14-5	2255-2263	approved	_
14-6	2264-2266	by	_
14-7	2267-2277	University	_
14-8	2278-2280	of	_
14-9	2281-2291	California	_
14-10	2292-2298	Irvine	_
14-11	2299-2300	,	_
14-12	2301-2311	University	_
14-13	2312-2314	of	_
14-14	2315-2325	California	_
14-15	2326-2329	San	_
14-16	2330-2339	Francisco	_
14-17	2340-2341	,	_
14-18	2342-2346	Duke	_
14-19	2347-2358	University/	_
14-20	2359-2369	University	_
14-21	2370-2372	of	_
14-22	2373-2378	North	_
14-23	2379-2387	Carolina	_
14-24	2388-2389	,	_
14-25	2390-2400	University	_
14-26	2401-2403	of	_
14-27	2404-2407	New	_
14-28	2408-2414	Mexico	_
14-29	2415-2416	,	_
14-30	2417-2427	University	_
14-31	2428-2430	of	_
14-32	2431-2435	Iowa	_
14-33	2436-2437	,	_
14-34	2438-2441	and	_
14-35	2442-2452	University	_
14-36	2453-2455	of	_
14-37	2456-2465	Minnesota	_
14-38	2466-2479	Institutional	_
14-39	2480-2486	Review	_
14-40	2487-2493	Boards	_
14-41	2494-2495	.	_

15-1	2496-2499	All	_
15-2	2500-2509	recruited	_
15-3	2510-2515	study	_
15-4	2516-2528	participants	_
15-5	2529-2533	were	_
15-6	2534-2541	between	_
15-7	2542-2545	the	_
15-8	2546-2550	ages	_
15-9	2551-2553	of	_
15-10	2554-2556	18	_
15-11	2557-2560	and	_
15-12	2561-2563	62	_
15-13	2564-2565	.	_

16-1	2566-2569	All	_
16-2	2570-2572	Sz	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-3	2573-2581	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-4	2582-2586	were	_
16-5	2587-2596	diagnosed	_
16-6	2597-2601	with	_
16-7	2602-2615	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-8	2616-2618	or	_
16-9	2619-2634	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
16-10	2635-2643	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
16-11	2644-2646	by	_
16-12	2647-2658	experienced	_
16-13	2659-2669	clinicians	_
16-14	2670-2675	using	_
16-15	2676-2679	the	_
16-16	2680-2690	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-17	2691-2699	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-18	2700-2709	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-19	2710-2713	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-20	2714-2723	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-21	2724-2728	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-22	2729-2730	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-23	2731-2740	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-24	2741-2742	.	_

17-1	2743-2751	Patients	_
17-2	2752-2756	were	_
17-3	2757-2763	either	_
17-4	2764-2770	stable	_
17-5	2771-2773	on	_
17-6	2774-2787	antipsychotic	_
17-7	2788-2798	medication	_
17-8	2799-2801	or	_
17-9	2802-2813	unmedicated	_
17-10	2814-2815	(	_
17-11	2816-2820	only	_
17-12	2821-2822	8	_
17-13	2823-2826	out	_
17-14	2827-2829	of	_
17-15	2830-2833	the	_
17-16	2834-2837	143	_
17-17	2838-2840	Sz	http://maven.renci.org/NeuroBridge/neurobridge#Thing
17-18	2841-2849	subjects	_
17-19	2850-2854	were	_
17-20	2855-2858	not	_
17-21	2859-2865	taking	_
17-22	2866-2879	antipsychotic	_
17-23	2880-2890	medication	_
17-24	2891-2893	at	_
17-25	2894-2897	the	_
17-26	2898-2902	time	_
17-27	2903-2905	of	_
17-28	2906-2909	the	_
17-29	2910-2915	study	_
17-30	2916-2917	)	_
17-31	2918-2919	.	_

18-1	2920-2927	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-2	2928-2936	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-3	2937-2941	with	_
18-4	2942-2943	a	_
18-5	2944-2956	first-degree	_
18-6	2957-2965	relative	_
18-7	2966-2970	with	_
18-8	2971-2973	an	_
18-9	2974-2978	Axis	_
18-10	2979-2980	I	_
18-11	2981-2989	disorder	_
18-12	2990-2992	or	_
18-13	2993-2994	a	_
18-14	2995-3002	history	_
18-15	3003-3005	of	_
18-16	3006-3011	major	_
18-17	3012-3023	psychiatric	_
18-18	3024-3031	illness	_
18-19	3032-3036	were	_
18-20	3037-3045	excluded	_
18-21	3046-3047	.	_

19-1	3048-3057	Exclusion	_
19-2	3058-3061	for	_
19-3	3062-3065	all	_
19-4	3066-3078	participants	_
19-5	3079-3087	included	_
19-6	3088-3095	history	_
19-7	3096-3098	of	_
19-8	3099-3104	major	_
19-9	3105-3112	medical	_
19-10	3113-3120	illness	_
19-11	3121-3122	,	_
19-12	3123-3135	insufficient	_
19-13	3136-3144	eyesight	_
19-14	3145-3147	to	_
19-15	3148-3151	see	_
19-16	3152-3156	with	_
19-17	3157-3163	normal	_
19-18	3164-3170	acuity	_
19-19	3171-3175	with	_
19-20	3176-3179	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-21	3180-3190	compatible	_
19-22	3191-3201	corrective	_
19-23	3202-3208	lenses	_
19-24	3209-3210	,	_
19-25	3211-3228	contraindications	_
19-26	3229-3232	for	_
19-27	3233-3236	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
19-28	3237-3238	,	_
19-29	3239-3243	drug	_
19-30	3244-3254	dependence	_
19-31	3255-3257	in	_
19-32	3258-3261	the	_
19-33	3262-3266	last	_
19-34	3267-3271	five	_
19-35	3272-3277	years	_
19-36	3278-3280	or	_
19-37	3281-3282	a	_
19-38	3283-3290	current	_
19-39	3291-3300	substance	_
19-40	3301-3306	abuse	_
19-41	3307-3315	disorder	_
19-42	3316-3317	,	_
19-43	3318-3320	an	_
19-44	3321-3333	intelligence	_
19-45	3334-3342	quotient	_
19-46	3343-3347	less	_
19-47	3348-3352	than	_
19-48	3353-3355	75	_
19-49	3356-3357	.	_

20-1	3358-3361	The	_
20-2	3362-3369	present	_
20-3	3370-3375	study	_
20-4	3376-3381	draws	_
20-5	3382-3386	from	_
20-6	3387-3390	the	_
20-7	3391-3396	FBIRN	_
20-8	3397-3402	Phase	_
20-9	3403-3406	III	_
20-10	3407-3412	study	_
20-11	3413-3414	(	_
20-12	3415-3418	see	_
20-13	3419-3420	)	_
20-14	3421-3422	.	_

21-1	3423-3431	Multiple	_
21-2	3432-3450	behavioral/symptom	_
21-3	3451-3462	assessments	_
21-4	3463-3467	were	_
21-5	3468-3477	performed	_
21-6	3478-3480	as	_
21-7	3481-3485	part	_
21-8	3486-3488	of	_
21-9	3489-3492	the	_
21-10	3493-3498	FBIRN	_
21-11	3499-3504	Phase	_
21-12	3505-3508	III	_
21-13	3509-3514	study	_
21-14	3515-3524	including	_
21-15	3525-3528	the	_
21-16	3529-3534	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-17	3535-3538	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-18	3539-3542	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-19	3543-3553	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-20	3554-3556	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-21	3557-3565	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-22	3566-3574	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-23	3575-3576	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-24	3577-3581	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-25	3582-3583	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
21-26	3584-3587	and	_
21-27	3588-3591	the	_
21-28	3592-3597	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-29	3598-3601	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-30	3602-3605	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-31	3606-3616	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-32	3617-3619	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-33	3620-3628	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-34	3629-3637	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-35	3638-3639	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-36	3640-3644	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-37	3645-3646	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
21-38	3647-3648	.	_

22-1	3649-3652	The	_
22-2	3653-3661	protocol	_
22-3	3662-3670	required	_
22-4	3671-3675	that	_
22-5	3676-3683	symptom	_
22-6	3684-3694	assessment	_
22-7	3695-3702	ratings	_
22-8	3703-3705	be	_
22-9	3706-3715	completed	_
22-10	3716-3722	within	_
22-11	3723-3726	one	_
22-12	3727-3732	month	_
22-13	3733-3735	of	_
22-14	3736-3744	scanning	_
22-15	3745-3746	.	_

23-1	3747-3750	For	_
23-2	3751-3752	a	_
23-3	3753-3761	detailed	_
23-4	3762-3773	description	_
23-5	3774-3776	of	_
23-6	3777-3780	the	_
23-7	3781-3792	multi-phase	_
23-8	3793-3798	FBIRN	_
23-9	3799-3806	project	_
23-10	3807-3816	including	_
23-11	3817-3824	subject	_
23-12	3825-3840	characteristics	_
23-13	3841-3842	,	_
23-14	3843-3850	imaging	_
23-15	3851-3861	parameters	_
23-16	3862-3863	,	_
23-17	3864-3867	and	_
23-18	3868-3876	behavior	_
23-19	3877-3888	assessments	_
23-20	3889-3892	see	_
23-21	3893-3894	.	_

24-1	3895-3898	2.2	_
24-2	3899-3900	.	_

25-1	3901-3909	Grouping	_
25-2	3910-3912	of	_
25-3	3913-3925	Participants	_
25-4	3926-3928	We	_
25-5	3929-3933	used	_
25-6	3934-3937	the	_
25-7	3938-3942	same	_
25-8	3943-3951	clinical	_
25-9	3952-3960	subgroup	_
25-10	3961-3968	sorting	_
25-11	3969-3977	strategy	_
25-12	3978-3982	used	_
25-13	3983-3993	previously	_
25-14	3994-3996	in	_
25-15	3997-4000	and	_
25-16	4001-4002	.	_

26-1	4003-4010	Sorting	_
26-2	4011-4013	of	_
26-3	4014-4017	the	_
26-4	4018-4021	141	_
26-5	4022-4024	Sz	_
26-6	4025-4029	into	_
26-7	4030-4038	clinical	_
26-8	4039-4048	subgroups	_
26-9	4049-4052	was	_
26-10	4053-4061	achieved	_
26-11	4062-4064	by	_
26-12	4065-4075	evaluating	_
26-13	4076-4085	responses	_
26-14	4086-4088	to	_
26-15	4089-4092	two	_
26-16	4093-4097	SAPS	_
26-17	4098-4103	items	_
26-18	4104-4105	.	_

27-1	4106-4110	Item	_
27-2	4111-4112	#	_
27-3	4113-4114	1	_
27-4	4115-4119	asks	_
27-5	4120-4122	if	_
27-6	4123-4126	the	_
27-7	4127-4138	participant	_
27-8	4139-4140	“	_
27-9	4141-4148	reports	_
27-10	4149-4155	voices	_
27-11	4156-4157	,	_
27-12	4158-4164	noises	_
27-13	4165-4166	,	_
27-14	4167-4169	or	_
27-15	4170-4175	other	_
27-16	4176-4182	sounds	_
27-17	4183-4187	that	_
27-18	4188-4190	no	_
27-19	4191-4194	one	_
27-20	4195-4199	else	_
27-21	4200-4205	hears	_
27-22	4206-4207	,	_
27-23	4208-4209	”	_
27-24	4210-4215	while	_
27-25	4216-4220	Item	_
27-26	4221-4222	#	_
27-27	4223-4224	6	_
27-28	4225-4229	asks	_
27-29	4230-4232	if	_
27-30	4233-4239	he/she	_
27-31	4240-4241	“	_
27-32	4242-4246	sees	_
27-33	4247-4253	shapes	_
27-34	4254-4256	or	_
27-35	4257-4263	people	_
27-36	4264-4268	that	_
27-37	4269-4272	are	_
27-38	4273-4276	not	_
27-39	4277-4285	actually	_
27-40	4286-4294	present.	_
27-41	4295-4296	”	_
27-42	4297-4301	Each	_
27-43	4302-4306	item	_
27-44	4307-4309	is	_
27-45	4310-4316	scored	_
27-46	4317-4322	using	_
27-47	4323-4324	a	_
27-48	4325-4326	1	_
27-49	4327-4329	to	_
27-50	4330-4331	5	_
27-51	4332-4338	rating	_
27-52	4339-4344	scale	_
27-53	4345-4346	(	_
27-54	4347-4348	0	_
27-55	4349-4350	=	_
27-56	4351-4354	not	_
27-57	4355-4362	present	_
27-58	4363-4364	;	_
27-59	4365-4366	1	_
27-60	4367-4368	=	_
27-61	4369-4381	questionable	_
27-62	4382-4383	;	_
27-63	4384-4385	2	_
27-64	4386-4387	=	_
27-65	4388-4392	mild	_
27-66	4393-4394	;	_
27-67	4395-4396	3	_
27-68	4397-4398	=	_
27-69	4399-4407	moderate	_
27-70	4408-4409	;	_
27-71	4410-4411	4	_
27-72	4412-4413	=	_
27-73	4414-4420	marked	_
27-74	4421-4422	;	_
27-75	4423-4424	5	_
27-76	4425-4426	=	_
27-77	4427-4433	severe	_
27-78	4434-4435	)	_
27-79	4436-4437	.	_

28-1	4438-4441	The	_
28-2	4442-4444	AH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-3	4445-4446	(	_
28-4	4447-4450	but	_
28-5	4451-4454	not	_
28-6	4455-4457	VH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
28-7	4458-4459	)	_
28-8	4460-4465	group	_
28-9	4466-4467	(	_
28-10	4468-4469	n	_
28-11	4470-4471	=	_
28-12	4472-4474	42	_
28-13	4475-4476	)	_
28-14	4477-4480	had	_
28-15	4481-4485	SAPS	_
28-16	4486-4490	Item	_
28-17	4491-4492	#	_
28-18	4493-4494	1	_
28-19	4495-4501	scores	_
28-20	4502-4503	>	_
28-21	4504-4505	1	_
28-22	4506-4509	and	_
28-23	4510-4514	SAPS	_
28-24	4515-4519	Item	_
28-25	4520-4521	#	_
28-26	4522-4523	6	_
28-27	4524-4530	scores	_
28-28	4531-4533	of	_
28-29	4534-4538	zero	_
28-30	4539-4540	.	_

29-1	4541-4544	The	_
29-2	4545-4561	non-hallucinator	_
29-3	4562-4567	group	_
29-4	4568-4569	(	_
29-5	4570-4572	NH	_
29-6	4573-4574	,	_
29-7	4575-4576	n	_
29-8	4577-4578	=	_
29-9	4579-4581	60	_
29-10	4582-4583	)	_
29-11	4584-4590	scored	_
29-12	4591-4595	zero	_
29-13	4596-4599	for	_
29-14	4600-4604	both	_
29-15	4605-4610	items	_
29-16	4611-4612	,	_
29-17	4613-4618	while	_
29-18	4619-4622	the	_
29-19	4623-4625	VH	_
29-20	4626-4631	group	_
29-21	4632-4633	(	_
29-22	4634-4635	n	_
29-23	4636-4637	=	_
29-24	4638-4640	39	_
29-25	4641-4642	)	_
29-26	4643-4646	had	_
29-27	4647-4651	SAPS	_
29-28	4652-4656	Item	_
29-29	4657-4658	#	_
29-30	4659-4660	6	_
29-31	4661-4667	scores	_
29-32	4668-4669	>	_
29-33	4670-4671	1	_
29-34	4672-4673	.	_

30-1	4674-4677	Due	_
30-2	4678-4680	to	_
30-3	4681-4691	prevalence	_
30-4	4692-4694	of	_
30-5	4695-4697	AH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-6	4698-4700	in	_
30-7	4701-4703	Sz	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-8	4704-4705	,	_
30-9	4706-4709	all	_
30-10	4710-4713	but	_
30-11	4714-4717	two	_
30-12	4718-4720	of	_
30-13	4721-4724	the	_
30-14	4725-4737	participants	_
30-15	4738-4740	in	_
30-16	4741-4744	the	_
30-17	4745-4747	VH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-18	4748-4756	subgroup	_
30-19	4757-4761	also	_
30-20	4762-4770	reported	_
30-21	4771-4773	AH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-22	4774-4775	(	_
30-23	4776-4778	95	_
30-24	4779-4780	%	_
30-25	4781-4782	)	_
30-26	4783-4784	.	_

31-1	4785-4788	For	_
31-2	4789-4790	a	_
31-3	4791-4797	subset	_
31-4	4798-4800	of	_
31-5	4801-4809	analyses	_
31-6	4810-4811	,	_
31-7	4812-4815	the	_
31-8	4816-4818	VH	_
31-9	4819-4822	and	_
31-10	4823-4825	AH	_
31-11	4826-4835	subgroups	_
31-12	4836-4840	were	_
31-13	4841-4847	pooled	_
31-14	4848-4850	to	_
31-15	4851-4855	form	_
31-16	4856-4857	a	_
31-17	4858-4871	hallucinating	_
31-18	4872-4873	(	_
31-19	4874-4878	HALL	_
31-20	4879-4880	)	_
31-21	4881-4889	subgroup	_
31-22	4890-4899	reporting	_
31-23	4900-4902	AH	_
31-24	4903-4904	,	_
31-25	4905-4907	VH	_
31-26	4908-4910	or	_
31-27	4911-4915	both	_
31-28	4916-4917	.	_

32-1	4918-4921	2.3	_
32-2	4922-4923	.	_

33-1	4924-4931	Imaging	_
33-2	4932-4936	Data	_
33-3	4937-4941	were	_
33-4	4942-4950	acquired	_
33-5	4951-4956	using	_
33-6	4957-4961	five	_
33-7	4962-4964	3T	_
33-8	4965-4972	Siemens	_
33-9	4973-4976	TIM	_
33-10	4977-4981	Trio	_
33-11	4982-4990	scanners	_
33-12	4991-4994	and	_
33-13	4995-4998	one	_
33-14	4999-5001	3T	_
33-15	5002-5004	GE	_
33-16	5005-5010	MR750	_
33-17	5011-5018	scanner	_
33-18	5019-5024	using	_
33-19	5025-5027	an	_
33-20	5028-5033	AC-PC	_
33-21	5034-5041	aligned	_
33-22	5042-5053	echo-planar	_
33-23	5054-5061	imaging	_
33-24	5062-5067	pulse	_
33-25	5068-5076	sequence	_
33-26	5077-5078	(	_
33-27	5079-5084	TR/TE	_
33-28	5085-5086	2	_
33-29	5087-5091	s/30	_
33-30	5092-5094	ms	_
33-31	5095-5096	,	_
33-32	5097-5101	flip	_
33-33	5102-5107	angle	_
33-34	5108-5111	77°	_
33-35	5112-5113	,	_
33-36	5114-5116	32	_
33-37	5117-5123	slices	_
33-38	5124-5133	collected	_
33-39	5134-5146	sequentially	_
33-40	5147-5151	from	_
33-41	5152-5160	superior	_
33-42	5161-5163	to	_
33-43	5164-5172	inferior	_
33-44	5173-5174	,	_
33-45	5175-5178	3.4	_
33-46	5179-5180	×	_
33-47	5181-5184	3.4	_
33-48	5185-5186	×	_
33-49	5187-5188	4	_
33-50	5189-5191	mm	_
33-51	5192-5196	with	_
33-52	5197-5199	mm	_
33-53	5200-5203	gap	_
33-54	5204-5205	,	_
33-55	5206-5209	162	_
33-56	5210-5216	frames	_
33-57	5217-5218	,	_
33-58	5219-5223	5:24	_
33-59	5224-5228	mins	_
33-60	5229-5230	)	_
33-61	5231-5233	to	_
33-62	5234-5240	obtain	_
33-63	5241-5243	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-64	5244-5245	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-65	5246-5255	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-66	5256-5262	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-67	5263-5264	.	_

34-1	5265-5273	Subjects	_
34-2	5274-5278	were	_
34-3	5279-5289	instructed	_
34-4	5290-5292	to	_
34-5	5293-5296	lie	_
34-6	5297-5299	in	_
34-7	5300-5303	the	_
34-8	5304-5311	scanner	_
34-9	5312-5316	with	_
34-10	5317-5321	eyes	_
34-11	5322-5328	closed	_
34-12	5329-5330	.	_

35-1	5331-5334	2.4	_
35-2	5335-5336	.	_

36-1	5337-5341	Data	_
36-2	5342-5352	Processing	_
36-3	5353-5367	Pre-processing	_
36-4	5368-5371	was	_
36-5	5372-5381	performed	_
36-6	5382-5387	using	_
36-7	5388-5391	the	_
36-8	5392-5396	Data	_
36-9	5397-5407	Processing	_
36-10	5408-5417	Assistant	_
36-11	5418-5421	for	_
36-12	5422-5435	Resting-State	_
36-13	5436-5440	fMRI	_
36-14	5441-5442	(	_
36-15	5443-5449	DPARSF	_
36-16	5450-5451	)	_
36-17	5452-5459	toolbox	_
36-18	5460-5465	which	_
36-19	5466-5470	runs	_
36-20	5471-5475	with	_
36-21	5476-5479	the	_
36-22	5480-5484	REST	_
36-23	5485-5493	software	_
36-24	5494-5495	.	_

37-1	5496-5499	The	_
37-2	5500-5505	first	_
37-3	5506-5509	two	_
37-4	5510-5514	time	_
37-5	5515-5521	frames	_
37-6	5522-5526	were	_
37-7	5527-5534	removed	_
37-8	5535-5537	to	_
37-9	5538-5543	allow	_
37-10	5544-5547	for	_
37-11	5548-5554	signal	_
37-12	5555-5568	stabilization	_
37-13	5569-5570	.	_

38-1	5571-5574	Raw	_
38-2	5575-5579	data	_
38-3	5580-5589	underwent	_
38-4	5590-5596	motion	_
38-5	5597-5607	correction	_
38-6	5608-5610	to	_
38-7	5611-5614	the	_
38-8	5615-5620	first	_
38-9	5621-5626	image	_
38-10	5627-5628	,	_
38-11	5629-5641	slice-timing	_
38-12	5642-5652	correction	_
38-13	5653-5655	to	_
38-14	5656-5659	the	_
38-15	5660-5666	middle	_
38-16	5667-5672	slice	_
38-17	5673-5674	,	_
38-18	5675-5688	normalization	_
38-19	5689-5691	to	_
38-20	5692-5695	MNI	_
38-21	5696-5701	space	_
38-22	5702-5703	,	_
38-23	5704-5707	and	_
38-24	5708-5715	spatial	_
38-25	5716-5725	smoothing	_
38-26	5726-5730	with	_
38-27	5731-5733	an	_
38-28	5734-5735	8	_
38-29	5736-5740	FWHM	_
38-30	5741-5749	Gaussian	_
38-31	5750-5756	kernel	_
38-32	5757-5758	.	_

39-1	5759-5768	Framewise	_
39-2	5769-5781	displacement	_
39-3	5782-5785	was	_
39-4	5786-5796	calculated	_
39-5	5797-5800	for	_
39-6	5801-5805	each	_
39-7	5806-5811	image	_
39-8	5812-5813	;	_
39-9	5814-5823	framewise	_
39-10	5824-5836	displacement	_
39-11	5837-5851	differentiates	_
39-12	5852-5856	head	_
39-13	5857-5868	realignment	_
39-14	5869-5879	parameters	_
39-15	5880-5886	across	_
39-16	5887-5893	frames	_
39-17	5894-5897	and	_
39-18	5898-5907	generates	_
39-19	5908-5909	a	_
39-20	5910-5923	6-dimensional	_
39-21	5924-5929	times	_
39-22	5930-5936	series	_
39-23	5937-5941	that	_
39-24	5942-5952	represents	_
39-25	5953-5966	instantaneous	_
39-26	5967-5971	head	_
39-27	5972-5978	motion	_
39-28	5979-5980	.	_

40-1	5981-5983	To	_
40-2	5984-5991	correct	_
40-3	5992-5995	for	_
40-4	5996-6007	confounding	_
40-5	6008-6015	effects	_
40-6	6016-6018	of	_
40-7	6019-6023	head	_
40-8	6024-6030	motion	_
40-9	6031-6033	on	_
40-10	6034-6037	the	_
40-11	6038-6042	fMRI	_
40-12	6043-6049	signal	_
40-13	6050-6051	,	_
40-14	6052-6054	we	_
40-15	6055-6063	included	_
40-16	6064-6068	mean	_
40-17	6069-6078	framewise	_
40-18	6079-6091	displacement	_
40-19	6092-6094	as	_
40-20	6095-6096	a	_
40-21	6097-6110	subject-level	_
40-22	6111-6120	covariate	_
40-23	6121-6122	.	_

41-1	6123-6126	2.5	_
41-2	6127-6128	.	_

42-1	6129-6134	Group	_
42-2	6135-6142	Spatial	_
42-3	6143-6154	Independent	_
42-4	6155-6164	Component	_
42-5	6165-6173	Analysis	_
42-6	6174-6176	We	_
42-7	6177-6186	performed	_
42-8	6187-6194	spatial	_
42-9	6195-6200	group	_
42-10	6201-6204	ICA	_
42-11	6205-6210	using	_
42-12	6211-6215	GIFT	_
42-13	6216-6224	software	_
42-14	6225-6226	.	_

43-1	6227-6230	One	_
43-2	6231-6238	hundred	_
43-3	6239-6250	independent	_
43-4	6251-6260	component	_
43-5	6261-6269	networks	_
43-6	6270-6274	were	_
43-7	6275-6283	obtained	_
43-8	6284-6288	from	_
43-9	6289-6292	the	_
43-10	6293-6298	group	_
43-11	6299-6308	principal	_
43-12	6309-6318	component	_
43-13	6319-6327	analysis	_
43-14	6328-6334	matrix	_
43-15	6335-6340	using	_
43-16	6341-6344	the	_
43-17	6345-6352	Infomax	_
43-18	6353-6362	algorithm	_
43-19	6363-6364	.	_

44-1	6365-6368	The	_
44-2	6369-6372	ICA	_
44-3	6373-6382	algorithm	_
44-4	6383-6386	was	_
44-5	6387-6395	repeated	_
44-6	6396-6402	twenty	_
44-7	6403-6408	times	_
44-8	6409-6411	in	_
44-9	6412-6418	ICASSO	_
44-10	6419-6422	and	_
44-11	6423-6426	the	_
44-12	6427-6431	most	_
44-13	6432-6439	central	_
44-14	6440-6446	result	_
44-15	6447-6450	was	_
44-16	6451-6455	used	_
44-17	6456-6458	to	_
44-18	6459-6465	ensure	_
44-19	6466-6475	stability	_
44-20	6476-6478	of	_
44-21	6479-6489	estimation	_
44-22	6490-6491	.	_

45-1	6492-6508	Subject-specific	_
45-2	6509-6516	spatial	_
45-3	6517-6521	maps	_
45-4	6522-6525	and	_
45-5	6526-6530	time	_
45-6	6531-6538	courses	_
45-7	6539-6543	were	_
45-8	6544-6552	obtained	_
45-9	6553-6558	using	_
45-10	6559-6563	back	_
45-11	6564-6578	reconstruction	_
45-12	6579-6590	implemented	_
45-13	6591-6593	in	_
45-14	6594-6598	GIFT	_
45-15	6599-6600	.	_

46-1	6601-6603	We	_
46-2	6604-6612	examined	_
46-3	6613-6626	z-transformed	_
46-4	6627-6634	spatial	_
46-5	6635-6639	maps	_
46-6	6640-6651	thresholded	_
46-7	6652-6654	at	_
46-8	6655-6656	z	_
46-9	6657-6658	>	_
46-10	6659-6660	3	_
46-11	6661-6663	to	_
46-12	6664-6672	identify	_
46-13	6673-6684	artifactual	_
46-14	6685-6689	RSNs	_
46-15	6690-6691	(	_
46-16	6692-6695	e.g	_
46-17	6696-6697	.	_

47-1	6698-6699	“	_
47-2	6700-6707	ringing	_
47-3	6708-6709	”	_
47-4	6710-6716	motion	_
47-5	6717-6726	artifacts	_
47-6	6727-6728	,	_
47-7	6729-6736	spatial	_
47-8	6737-6741	maps	_
47-9	6742-6746	with	_
47-10	6747-6751	peak	_
47-11	6752-6758	signal	_
47-12	6759-6766	arising	_
47-13	6767-6771	from	_
47-14	6772-6781	CSF/white	_
47-15	6782-6788	matter	_
47-16	6789-6790	)	_
47-17	6791-6792	.	_

48-1	6793-6798	Using	_
48-2	6799-6802	the	_
48-3	6803-6809	method	_
48-4	6810-6818	proposed	_
48-5	6819-6821	by	_
48-6	6822-6823	,	_
48-7	6824-6826	we	_
48-8	6827-6836	discarded	_
48-9	6837-6847	components	_
48-10	6848-6852	with	_
48-11	6853-6857	poor	_
48-12	6858-6861	low	_
48-13	6862-6876	frequency/high	_
48-14	6877-6886	frequency	_
48-15	6887-6892	power	_
48-16	6893-6899	ratios	_
48-17	6900-6901	,	_
48-18	6902-6905	and	_
48-19	6906-6911	those	_
48-20	6912-6916	with	_
48-21	6917-6926	stability	_
48-22	6927-6936	quotients	_
48-23	6937-6938	<	_
48-24	6939-6943	0.85	_
48-25	6944-6945	.	_

49-1	6946-6950	From	_
49-2	6951-6954	the	_
49-3	6955-6964	remaining	_
49-4	6965-6969	RSNs	_
49-5	6970-6971	,	_
49-6	6972-6976	nine	_
49-7	6977-6985	networks	_
49-8	6986-6988	of	_
49-9	6989-6997	interest	_
49-10	6998-7002	were	_
49-11	7003-7011	selected	_
49-12	7012-7013	:	_
49-13	7014-7017	two	_
49-14	7018-7024	visual	_
49-15	7025-7029	RSNS	_
49-16	7030-7031	,	_
49-17	7032-7035	two	_
49-18	7036-7044	auditory	_
49-19	7045-7049	RSNs	_
49-20	7050-7051	,	_
49-21	7052-7054	SN	_
49-22	7055-7056	,	_
49-23	7057-7065	anterior	_
49-24	7066-7069	DMN	_
49-25	7070-7071	,	_
49-26	7072-7081	posterior	_
49-27	7082-7085	DMN	_
49-28	7086-7087	,	_
49-29	7088-7097	bilateral	_
49-30	7098-7105	putamen	_
49-31	7106-7107	,	_
49-32	7108-7111	and	_
49-33	7112-7121	bilateral	_
49-34	7122-7133	hippocampus	_
49-35	7134-7135	(	_
49-36	7136-7142	Figure	_
49-37	7143-7144	1	_
49-38	7145-7146	,	_
49-39	7147-7152	Table	_
49-40	7153-7154	2	_
49-41	7155-7156	)	_
49-42	7157-7158	.	_

50-1	7159-7166	Subject	_
50-2	7167-7178	timecourses	_
50-3	7179-7183	were	_
50-4	7184-7193	detrended	_
50-5	7194-7197	and	_
50-6	7198-7206	despiked	_
50-7	7207-7208	,	_
50-8	7209-7213	then	_
50-9	7214-7222	filtered	_
50-10	7223-7227	with	_
50-11	7228-7229	a	_
50-12	7230-7234	high	_
50-13	7235-7244	frequency	_
50-14	7245-7251	cutoff	_
50-15	7252-7254	of	_
50-16	7255-7259	0.15	_
50-17	7260-7262	Hz	_
50-18	7263-7268	prior	_
50-19	7269-7271	to	_
50-20	7272-7281	computing	_
50-21	7282-7285	FNC	_
50-22	7286-7298	correlations	_
50-23	7299-7300	;	_
50-24	7301-7304	FNC	_
50-25	7305-7317	correlations	_
50-26	7318-7321	are	_
50-27	7322-7329	defined	_
50-28	7330-7332	as	_
50-29	7333-7336	the	_
50-30	7337-7345	pairwise	_
50-31	7346-7358	correlations	_
50-32	7359-7366	between	_
50-33	7367-7374	network	_
50-34	7375-7379	time	_
50-35	7380-7387	courses	_
50-36	7388-7389	.	_

51-1	7390-7393	For	_
51-2	7394-7397	all	_
51-3	7398-7401	FNC	_
51-4	7402-7410	analyses	_
51-5	7411-7412	,	_
51-6	7413-7416	FNC	_
51-7	7417-7429	correlations	_
51-8	7430-7434	were	_
51-9	7435-7446	transformed	_
51-10	7447-7449	to	_
51-11	7450-7458	z-scores	_
51-12	7459-7464	using	_
51-13	7465-7471	Fisher	_
51-14	7472-7473	’	_
51-15	7474-7475	s	_
51-16	7476-7490	transformation	_
51-17	7491-7492	.	_

52-1	7493-7496	2.6	_
52-2	7497-7498	.	_

53-1	7499-7510	Statistical	_
53-2	7511-7519	Analyses	_
53-3	7520-7525	2.6.1	_
53-4	7526-7527	.	_

54-1	7528-7533	Group	_
54-2	7534-7545	Differences	_
54-3	7546-7548	We	_
54-4	7549-7558	performed	_
54-5	7559-7560	a	_
54-6	7561-7571	two-sample	_
54-7	7572-7578	t-test	_
54-8	7579-7580	(	_
54-9	7581-7583	HC	_
54-10	7584-7587	vs.	_
54-11	7588-7590	Sz	_
54-12	7591-7592	)	_
54-13	7593-7595	to	_
54-14	7596-7603	explore	_
54-15	7604-7607	FNC	_
54-16	7608-7620	correlations	_
54-17	7621-7631	associated	_
54-18	7632-7636	with	_
54-19	7637-7639	Sz	_
54-20	7640-7649	diagnosis	_
54-21	7650-7651	.	_

55-1	7652-7654	We	_
55-2	7655-7663	examined	_
55-3	7664-7671	changes	_
55-4	7672-7674	in	_
55-5	7675-7678	FNC	_
55-6	7679-7689	associated	_
55-7	7690-7694	with	_
55-8	7695-7698	the	_
55-9	7699-7706	general	_
55-10	7707-7712	trait	_
55-11	7713-7715	to	_
55-12	7716-7726	experience	_
55-13	7727-7741	hallucinations	_
55-14	7742-7743	(	_
55-15	7744-7746	AH	_
55-16	7747-7748	,	_
55-17	7749-7751	VH	_
55-18	7752-7754	or	_
55-19	7755-7759	both	_
55-20	7760-7761	)	_
55-21	7762-7766	with	_
55-22	7767-7768	a	_
55-23	7769-7780	three-group	_
55-24	7781-7786	level	_
55-25	7787-7793	ANCOVA	_
55-26	7794-7795	(	_
55-27	7796-7800	HALL	_
55-28	7801-7802	,	_
55-29	7803-7805	NH	_
55-30	7806-7807	,	_
55-31	7808-7810	HC	_
55-32	7811-7812	)	_
55-33	7813-7814	;	_
55-34	7815-7818	FNC	_
55-35	7819-7829	associated	_
55-36	7830-7834	with	_
55-37	7835-7852	modality-specific	_
55-38	7853-7867	hallucinations	_
55-39	7868-7871	was	_
55-40	7872-7880	explored	_
55-41	7881-7886	using	_
55-42	7887-7888	a	_
55-43	7889-7899	four-group	_
55-44	7900-7905	level	_
55-45	7906-7912	ANCOVA	_
55-46	7913-7914	(	_
55-47	7915-7917	VH	_
55-48	7918-7919	,	_
55-49	7920-7922	AH	_
55-50	7923-7924	,	_
55-51	7925-7927	NH	_
55-52	7928-7929	,	_
55-53	7930-7932	HC	_
55-54	7933-7934	)	_
55-55	7935-7936	.	_

56-1	7937-7940	Age	_
56-2	7941-7942	,	_
56-3	7943-7951	scanning	_
56-4	7952-7956	site	_
56-5	7957-7958	,	_
56-6	7959-7965	gender	_
56-7	7966-7967	,	_
56-8	7968-7971	and	_
56-9	7972-7976	mean	_
56-10	7977-7986	framewise	_
56-11	7987-7999	displacement	_
56-12	8000-8004	were	_
56-13	8005-8013	included	_
56-14	8014-8016	as	_
56-15	8017-8027	covariates	_
56-16	8028-8029	.	_

57-1	8030-8041	Statistical	_
57-2	8042-8054	significance	_
57-3	8055-8058	was	_
57-4	8059-8060	a	_
57-5	8061-8067	priori	_
57-6	8068-8077	specified	_
57-7	8078-8080	as	_
57-8	8081-8082	p	_
57-9	8083-8084	<	_
57-10	8085-8089	0.05	_
57-11	8090-8095	using	_
57-12	8096-8097	a	_
57-13	8098-8103	false	_
57-14	8104-8113	discovery	_
57-15	8114-8118	rate	_
57-16	8119-8120	(	_
57-17	8121-8124	FDR	_
57-18	8125-8126	)	_
57-19	8127-8137	correction	_
57-20	8138-8141	for	_
57-21	8142-8150	multiple	_
57-22	8151-8162	comparisons	_
57-23	8163-8164	.	_

58-1	8165-8170	2.6.2	_
58-2	8171-8172	.	_

59-1	8173-8180	Symptom	_
59-2	8181-8189	Severity	_
59-3	8190-8191	&	_
59-4	8192-8195	FNC	_
59-5	8196-8197	:	_
59-6	8198-8208	Regression	_
59-7	8209-8217	Analyses	_
59-8	8218-8220	To	_
59-9	8221-8225	test	_
59-10	8226-8229	the	_
59-11	8230-8240	hypothesis	_
59-12	8241-8245	that	_
59-13	8246-8254	abnormal	_
59-14	8255-8258	FNC	_
59-15	8259-8266	between	_
59-16	8267-8275	salience	_
59-17	8276-8279	and	_
59-18	8280-8287	sensory	_
59-19	8288-8296	networks	_
59-20	8297-8306	underlies	_
59-21	8307-8324	modality-specific	_
59-22	8325-8339	hallucinations	_
59-23	8340-8341	,	_
59-24	8342-8344	we	_
59-25	8345-8354	performed	_
59-26	8355-8361	linear	_
59-27	8362-8372	regression	_
59-28	8373-8381	analyses	_
59-29	8382-8384	of	_
59-30	8385-8388	FNC	_
59-31	8389-8390	.	_

60-1	8391-8393	To	_
60-2	8394-8400	ensure	_
60-3	8401-8405	that	_
60-4	8406-8414	observed	_
60-5	8415-8427	associations	_
60-6	8428-8435	between	_
60-7	8436-8441	AH/VH	_
60-8	8442-8450	severity	_
60-9	8451-8454	and	_
60-10	8455-8458	FNC	_
60-11	8459-8463	were	_
60-12	8464-8467	not	_
60-13	8468-8474	driven	_
60-14	8475-8477	or	_
60-15	8478-8488	influenced	_
60-16	8489-8491	by	_
60-17	8492-8503	confounding	_
60-18	8504-8511	factors	_
60-19	8512-8513	,	_
60-20	8514-8516	we	_
60-21	8517-8524	modeled	_
60-22	8525-8532	effects	_
60-23	8533-8535	of	_
60-24	8536-8544	nuisance	_
60-25	8545-8555	covariates	_
60-26	8556-8557	(	_
60-27	8558-8561	age	_
60-28	8562-8563	,	_
60-29	8564-8570	gender	_
60-30	8571-8572	,	_
60-31	8573-8576	and	_
60-32	8577-8581	mean	_
60-33	8582-8591	framewise	_
60-34	8592-8604	displacement	_
60-35	8605-8606	;	_
60-36	8607-8615	scanning	_
60-37	8616-8620	site	_
60-38	8621-8624	was	_
60-39	8625-8630	dummy	_
60-40	8631-8636	coded	_
60-41	8637-8640	and	_
60-42	8641-8648	modeled	_
60-43	8649-8651	as	_
60-44	8652-8653	a	_
60-45	8654-8660	random	_
60-46	8661-8667	effect	_
60-47	8668-8669	)	_
60-48	8670-8671	.	_

61-1	8672-8677	Since	_
61-2	8678-8686	nicotine	_
61-3	8687-8690	use	_
61-4	8691-8693	is	_
61-5	8694-8697	2–3	_
61-6	8698-8703	times	_
61-7	8704-8710	higher	_
61-8	8711-8713	in	_
61-9	8714-8716	Sz	http://maven.renci.org/NeuroBridge/neurobridge#Thing
61-10	8717-8721	than	_
61-11	8722-8724	in	_
61-12	8725-8728	the	_
61-13	8729-8736	healthy	_
61-14	8737-8747	population	_
61-15	8748-8749	,	_
61-16	8750-8753	and	_
61-17	8754-8757	has	_
61-18	8758-8762	been	_
61-19	8763-8768	shown	_
61-20	8769-8771	to	_
61-21	8772-8785	significantly	_
61-22	8786-8792	impact	_
61-23	8793-8798	brain	_
61-24	8799-8809	functional	_
61-25	8810-8822	connectivity	_
61-26	8823-8824	,	_
61-27	8825-8827	we	_
61-28	8828-8836	examined	_
61-29	8837-8845	Spearman	_
61-30	8846-8858	correlations	_
61-31	8859-8866	between	_
61-32	8867-8870	FNC	_
61-33	8871-8874	and	_
61-34	8875-8882	smoking	_
61-35	8883-8889	status	_
61-36	8890-8891	(	_
61-37	8892-8898	factor	_
61-38	8899-8903	with	_
61-39	8904-8909	three	_
61-40	8910-8916	levels	_
61-41	8917-8918	:	_
61-42	8919-8920	“	_
61-43	8921-8926	never	_
61-44	8927-8933	smoker	_
61-45	8934-8935	”	_
61-46	8936-8937	,	_
61-47	8938-8939	“	_
61-48	8940-8949	ex-smoker	_
61-49	8950-8951	”	_
61-50	8952-8953	,	_
61-51	8954-8955	“	_
61-52	8956-8963	current	_
61-53	8964-8970	smoker	_
61-54	8971-8972	”	_
61-55	8973-8974	)	_
61-56	8975-8977	in	_
61-57	8978-8981	our	_
61-58	8982-8988	sample	_
61-59	8989-8991	of	_
61-60	8992-8995	294	_
61-61	8996-9004	subjects	_
61-62	9005-9006	.	_

62-1	9007-9012	These	_
62-2	9013-9021	analyses	_
62-3	9022-9030	revealed	_
62-4	9031-9032	a	_
62-5	9033-9044	significant	_
62-6	9045-9056	association	_
62-7	9057-9064	between	_
62-8	9065-9072	smoking	_
62-9	9073-9079	status	_
62-10	9080-9083	and	_
62-11	9084-9090	SN-STG	_
62-12	9091-9092	(	_
62-13	9093-9095	BA	_
62-14	9096-9098	22	_
62-15	9099-9100	)	_
62-16	9101-9104	FNC	_
62-17	9105-9106	(	_
62-18	9107-9110	rho	_
62-19	9111-9112	=	_
62-20	9113-9119	−0.244	_
62-21	9120-9121	,	_
62-22	9122-9123	p	_
62-23	9124-9125	<	_
62-24	9126-9130	0.01	_
62-25	9131-9132	)	_
62-26	9133-9134	,	_
62-27	9135-9137	so	_
62-28	9138-9145	smoking	_
62-29	9146-9152	status	_
62-30	9153-9156	was	_
62-31	9157-9165	included	_
62-32	9166-9168	as	_
62-33	9169-9171	an	_
62-34	9172-9182	additional	_
62-35	9183-9192	covariate	_
62-36	9193-9194	.	_

63-1	9195-9197	To	_
63-2	9198-9205	confirm	_
63-3	9206-9210	that	_
63-4	9211-9219	observed	_
63-5	9220-9227	effects	_
63-6	9228-9230	of	_
63-7	9231-9236	VH/AH	_
63-8	9237-9245	severity	_
63-9	9246-9248	on	_
63-10	9249-9252	FNC	_
63-11	9253-9257	were	_
63-12	9258-9261	not	_
63-13	9262-9268	driven	_
63-14	9269-9271	by	_
63-15	9272-9283	confounding	_
63-16	9284-9291	effects	_
63-17	9292-9294	of	_
63-18	9295-9308	antipsychotic	_
63-19	9309-9319	medication	_
63-20	9320-9321	,	_
63-21	9322-9324	we	_
63-22	9325-9334	performed	_
63-23	9335-9343	post-hoc	_
63-24	9344-9354	regression	_
63-25	9355-9363	analyses	_
63-26	9364-9366	of	_
63-27	9367-9370	FNC	_
63-28	9371-9372	,	_
63-29	9373-9382	including	_
63-30	9383-9388	total	_
63-31	9389-9403	chlorpromazine	_
63-32	9404-9415	equivalents	_
63-33	9416-9418	as	_
63-34	9419-9421	an	_
63-35	9422-9432	additional	_
63-36	9433-9442	covariate	_
63-37	9443-9444	.	_

64-1	9445-9447	We	_
64-2	9448-9454	lacked	_
64-3	9455-9466	information	_
64-4	9467-9469	to	_
64-5	9470-9476	derive	_
64-6	9477-9491	chlorpromazine	_
64-7	9492-9503	equivalents	_
64-8	9504-9507	for	_
64-9	9508-9510	18	_
64-10	9511-9513	Sz	_
64-11	9514-9522	subjects	_
64-12	9523-9524	,	_
64-13	9525-9527	so	_
64-14	9528-9531	the	_
64-15	9532-9536	mean	_
64-16	9537-9542	value	_
64-17	9543-9545	of	_
64-18	9546-9551	total	_
64-19	9552-9566	chlorpromazine	_
64-20	9567-9578	equivalents	_
64-21	9579-9582	was	_
64-22	9583-9593	calculated	_
64-23	9594-9595	(	_
64-24	9596-9601	based	_
64-25	9602-9604	on	_
64-26	9605-9608	the	_
64-27	9609-9618	available	_
64-28	9619-9623	data	_
64-29	9624-9625	)	_
64-30	9626-9627	,	_
64-31	9628-9631	and	_
64-32	9632-9644	interpolated	_
64-33	9645-9648	for	_
64-34	9649-9654	those	_
64-35	9655-9663	subjects	_
64-36	9664-9668	with	_
64-37	9669-9676	missing	_
64-38	9677-9681	data	_
64-39	9682-9683	.	_

65-1	9684-9687	For	_
65-2	9688-9691	all	_
65-3	9692-9700	analyses	_
65-4	9701-9702	,	_
65-5	9703-9713	confidence	_
65-6	9714-9717	was	_
65-7	9718-9727	specified	_
65-8	9728-9730	as	_
65-9	9731-9732	p	_
65-10	9733-9734	<	_
65-11	9735-9739	0.05	_
65-12	9740-9741	.	_

66-1	9742-9747	2.6.3	_
66-2	9748-9759	Hippocampal	_
66-3	9760-9764	ALFF	_
66-4	9765-9766	&	_
66-5	9767-9770	FNC	_
66-6	9771-9772	:	_
66-7	9773-9783	Regression	_
66-8	9784-9792	Analyses	_
66-9	9793-9802	Voxelwise	_
66-10	9803-9807	mean	_
66-11	9808-9812	ALFF	_
66-12	9813-9817	maps	_
66-13	9818-9822	were	_
66-14	9823-9831	computed	_
66-15	9832-9835	for	_
66-16	9836-9840	each	_
66-17	9841-9848	subject	_
66-18	9849-9854	using	_
66-19	9855-9859	REST	_
66-20	9860-9868	software	_
66-21	9869-9871	as	_
66-22	9872-9881	described	_
66-23	9882-9884	in	_
66-24	9885-9888	The	_
66-25	9889-9893	left	_
66-26	9894-9905	hippocampal	_
66-27	9906-9913	cluster	_
66-28	9914-9918	that	_
66-29	9919-9925	showed	_
66-30	9926-9937	significant	_
66-31	9938-9942	ALFF	_
66-32	9943-9952	variation	_
66-33	9953-9959	across	_
66-34	9960-9962	VH	_
66-35	9963-9966	vs.	_
66-36	9967-9969	AH	_
66-37	9970-9979	subgroups	_
66-38	9980-9982	in	_
66-39	9983-9984	,	_
66-40	9985-9988	was	_
66-41	9989-9994	saved	_
66-42	9995-9997	as	_
66-43	9998-9999	a	_
66-44	10000-10006	binary	_
66-45	10007-10011	mask	_
66-46	10012-10013	.	_

67-1	10014-10030	Subject-specific	_
67-2	10031-10039	weighted	_
67-3	10040-10044	ALFF	_
67-4	10045-10053	averages	_
67-5	10054-10060	within	_
67-6	10061-10065	this	_
67-7	10066-10073	cluster	_
67-8	10074-10078	were	_
67-9	10079-10086	derived	_
67-10	10087-10091	from	_
67-11	10092-10095	the	_
67-12	10096-10099	294	_
67-13	10100-10104	ALFF	_
67-14	10105-10109	maps	_
67-15	10110-10115	using	_
67-16	10116-10119	SPM	_
67-17	10120-10121	’	_
67-18	10122-10123	s	_
67-19	10124-10131	MARSBAR	_
67-20	10132-10139	utility	_
67-21	10140-10141	.	_

68-1	10142-10144	We	_
68-2	10145-10155	calculated	_
68-3	10156-10159	the	_
68-4	10160-10172	relationship	_
68-5	10173-10180	between	_
68-6	10181-10186	these	_
68-7	10187-10203	subject-specific	_
68-8	10204-10215	hippocampal	_
68-9	10216-10220	ALFF	_
68-10	10221-10229	averages	_
68-11	10230-10233	and	_
68-12	10234-10237	FNC	_
68-13	10238-10240	to	_
68-14	10241-10248	explore	_
68-15	10249-10256	whether	_
68-16	10257-10260	the	_
68-17	10261-10267	nature	_
68-18	10268-10274	and/or	_
68-19	10275-10283	strength	_
68-20	10284-10286	of	_
68-21	10287-10295	ALFF-FNC	_
68-22	10296-10309	relationships	_
68-23	10310-10313	are	_
68-24	10314-10323	different	_
68-25	10324-10326	in	_
68-26	10327-10329	Sz	_
68-27	10330-10333	vs.	_
68-28	10334-10336	HC	_
68-29	10337-10338	.	_

69-1	10339-10343	Only	_
69-2	10344-10347	FNC	_
69-3	10348-10360	correlations	_
69-4	10361-10365	that	_
69-5	10366-10370	were	_
69-6	10371-10384	significantly	_
69-7	10385-10394	different	_
69-8	10395-10401	across	_
69-9	10402-10404	Sz	_
69-10	10405-10408	and	_
69-11	10409-10411	HC	_
69-12	10412-10414	in	_
69-13	10415-10418	the	_
69-14	10419-10424	group	_
69-15	10425-10433	analysis	_
69-16	10434-10438	were	_
69-17	10439-10447	examined	_
69-18	10448-10450	in	_
69-19	10451-10456	these	_
69-20	10457-10465	ALFF-FNC	_
69-21	10466-10476	regression	_
69-22	10477-10485	analyses	_
69-23	10486-10487	.	_

70-1	10488-10493	First	_
70-2	10494-10495	,	_
70-3	10496-10498	we	_
70-4	10499-10507	examined	_
70-5	10508-10517	potential	_
70-6	10518-10522	ALFF	_
70-7	10523-10524	x	_
70-8	10525-10534	diagnosis	_
70-9	10535-10547	interactions	_
70-10	10548-10550	in	_
70-11	10551-10552	a	_
70-12	10553-10559	linear	_
70-13	10560-10570	regression	_
70-14	10571-10579	analysis	_
70-15	10580-10581	.	_

71-1	10582-10585	Age	_
71-2	10586-10587	,	_
71-3	10588-10594	gender	_
71-4	10595-10596	,	_
71-5	10597-10601	mean	_
71-6	10602-10611	framewise	_
71-7	10612-10624	displacement	_
71-8	10625-10626	,	_
71-9	10627-10630	and	_
71-10	10631-10638	smoking	_
71-11	10639-10645	status	_
71-12	10646-10650	were	_
71-13	10651-10659	included	_
71-14	10660-10662	as	_
71-15	10663-10673	covariates	_
71-16	10674-10675	;	_
71-17	10676-10684	scanning	_
71-18	10685-10689	site	_
71-19	10690-10693	was	_
71-20	10694-10701	modeled	_
71-21	10702-10704	as	_
71-22	10705-10706	a	_
71-23	10707-10713	random	_
71-24	10714-10720	effect	_
71-25	10721-10722	.	_

72-1	10723-10725	To	_
72-2	10726-10733	further	_
72-3	10734-10739	probe	_
72-4	10740-10747	whether	_
72-5	10748-10751	the	_
72-6	10752-10758	nature	_
72-7	10759-10765	and/or	_
72-8	10766-10774	strength	_
72-9	10775-10777	of	_
72-10	10778-10786	ALFF-FNC	_
72-11	10787-10800	relationships	_
72-12	10801-10804	are	_
72-13	10805-10814	different	_
72-14	10815-10817	in	_
72-15	10818-10820	Sz	_
72-16	10821-10824	vs.	_
72-17	10825-10827	HC	_
72-18	10828-10829	,	_
72-19	10830-10832	we	_
72-20	10833-10841	explored	_
72-21	10842-10850	ALFF-FNC	_
72-22	10851-10863	associations	_
72-23	10864-10866	in	_
72-24	10867-10875	separate	_
72-25	10876-10884	analyses	_
72-26	10885-10887	of	_
72-27	10888-10890	HC	_
72-28	10891-10894	and	_
72-29	10895-10897	Sz	_
72-30	10898-10899	.	_

73-1	10900-10902	We	_
73-2	10903-10910	modeled	_
73-3	10911-10918	effects	_
73-4	10919-10921	of	_
73-5	10922-10933	hippocampal	_
73-6	10934-10938	ALFF	_
73-7	10939-10941	on	_
73-8	10942-10945	FNC	_
73-9	10946-10947	,	_
73-10	10948-10959	controlling	_
73-11	10960-10963	for	_
73-12	10964-10975	confounding	_
73-13	10976-10986	influences	_
73-14	10987-10989	on	_
73-15	10990-10993	FNC	_
73-16	10994-10995	(	_
73-17	10996-10999	age	_
73-18	11000-11001	,	_
73-19	11002-11008	gender	_
73-20	11009-11010	,	_
73-21	11011-11015	mean	_
73-22	11016-11025	framewise	_
73-23	11026-11038	displacement	_
73-24	11039-11040	,	_
73-25	11041-11048	smoking	_
73-26	11049-11055	status	_
73-27	11056-11057	,	_
73-28	11058-11061	and	_
73-29	11062-11068	random	_
73-30	11069-11076	effects	_
73-31	11077-11079	of	_
73-32	11080-11088	scanning	_
73-33	11089-11093	site	_
73-34	11094-11095	)	_
73-35	11096-11098	in	_
73-36	11099-11102	the	_
73-37	11103-11109	linear	_
73-38	11110-11115	model	_
73-39	11116-11117	.	_

74-1	11118-11126	Separate	_
74-2	11127-11137	regression	_
74-3	11138-11146	analyses	_
74-4	11147-11151	were	_
74-5	11152-11161	performed	_
74-6	11162-11164	in	_
74-7	11165-11169	HALL	_
74-8	11170-11173	and	_
74-9	11174-11176	NH	_
74-10	11177-11179	to	_
74-11	11180-11187	address	_
74-12	11188-11191	the	_
74-13	11192-11200	question	_
74-14	11201-11203	of	_
74-15	11204-11211	whether	_
74-16	11212-11220	abnormal	_
74-17	11221-11229	ALFF-FNC	_
74-18	11230-11242	associations	_
74-19	11243-11246	are	_
74-20	11247-11255	observed	_
74-21	11256-11258	in	_
74-22	11259-11261	Sz	_
74-23	11262-11271	reporting	_
74-24	11272-11286	hallucinations	_
74-25	11287-11298	exclusively	_
74-26	11299-11301	or	_
74-27	11302-11306	were	_
74-28	11307-11311	also	_
74-29	11312-11320	observed	_
74-30	11321-11323	in	_
74-31	11324-11326	NH	_
74-32	11327-11335	patients	_
74-33	11336-11337	.	_

75-1	11338-11340	We	_
75-2	11341-11350	confirmed	_
75-3	11351-11355	that	_
75-4	11356-11364	observed	_
75-5	11365-11377	associations	_
75-6	11378-11385	between	_
75-7	11386-11397	hippocampal	_
75-8	11398-11402	ALFF	_
75-9	11403-11406	and	_
75-10	11407-11410	FNC	_
75-11	11411-11415	were	_
75-12	11416-11419	not	_
75-13	11420-11426	driven	_
75-14	11427-11429	by	_
75-15	11430-11441	confounding	_
75-16	11442-11449	effects	_
75-17	11450-11452	of	_
75-18	11453-11466	antipsychotic	_
75-19	11467-11477	medication	_
75-20	11478-11480	by	_
75-21	11481-11491	performing	_
75-22	11492-11500	post-hoc	_
75-23	11501-11511	regression	_
75-24	11512-11520	analyses	_
75-25	11521-11522	,	_
75-26	11523-11532	including	_
75-27	11533-11538	total	_
75-28	11539-11553	chlorpromazine	_
75-29	11554-11565	equivalents	_
75-30	11566-11568	as	_
75-31	11569-11571	an	_
75-32	11572-11582	additional	_
75-33	11583-11592	covariate	_
75-34	11593-11594	.	_

76-1	11595-11605	Confidence	_
76-2	11606-11609	was	_
76-3	11610-11619	specified	_
76-4	11620-11622	as	_
76-5	11623-11624	p	_
76-6	11625-11626	<	_
76-7	11627-11631	0.05	_
76-8	11632-11633	.	_

